Galectin-3 Immunoassay
AssigneeBG Medicine, Inc.
InventorPieter Muntendam
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
Claims21
A kit for detecting the concentration of galectin-3 in a sample, the kit comprising
- first and second binding moieties, one being labeled with a detectable label, each binding respectively to spaced-apart epitopes on the N-terminal portion of galectin-3, which comprises the sequence of amino acids:
- (SEQ ID NO:
- 1)
- MADNFSLHDA LSGSGNPNPQ GWPGAWGNQP AGAGGYPGAS
- YPGAYPGQAP PGAYPGQAPP GAYPGAPGAY PGAPAPGVYP
- GPPSGPGAYP SSGQPSATGA YPATGPYGAP AGP.
A method for detecting the level of human galectin-3 in a sample from a subject, the method comprising:
- subjecting the sample to a double binding moiety sandwich assay, at least one of the binding moieties being labeled with a detectable label, each of the binding moieties being specific for respective, non-overlapping epitopes on the N-terminal portion of galectin-3, which comprises the sequence of amino acids:
- (SEQ ID NO:
- 1)
- MADNFSLHDA LSGSGNPNPQ GWPGAWGNQP AGAGGYPGAS
- YPGAYPGQAP PGAYPGQAPP GAYPGAPGAY PGAPAPGVYP
- GPPSGPGAYP SSGQPSATGA YPATGPYGAP AGP.
A method for detecting a risk of development or progression of heart failure in a subject, the method comprising determining whether the galectin-3 concentration in a sample from the subject exceeds a threshold of at least 15 ng/ml.
Dependencies are inferred from the claim text.